WAC/RET: A Novel RET Oncogenic Fusion Variant in Non-Small Cell Lung Carcinoma

被引：8
|
作者：
Velcheti, Vamsidhar [1 ]
Madison, Russell [2 ]
Ali, Siraj M. [2 ]
Schrock, Alexa B. [2 ]
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
[2] Fdn Med, Cambridge, MA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 07期
关键词：
D O I：
10.1016/j.jtho.2018.03.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E122 / E123
页数：3
相关论文
共 50 条
  • [21] Pralsetinib: Treatment of metastatic RET fusion-positive non-small cell lung cancer
    Nguyen, Ly
    Monestime, Shanada
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (07) : 527 - 533
  • [22] Real-world outcomes of immune checkpoint inhibitors and selective RET inhibitors for RET fusion non-small cell lung cancer
    Wan, R.
    Duan, J.
    Wang, Z.
    Lin, L.
    Li, W.
    Jie, W.
    ANNALS OF ONCOLOGY, 2022, 33 : S54 - S54
  • [23] RET inhibitors for patients with RET fusion-positive and RET wild-type non-small-cell lung cancer
    Rosell, Rafael
    Karachaliou, Niki
    LANCET ONCOLOGY, 2016, 17 (12): : 1623 - +
  • [24] Novel qPCR screen for efficient and reliable identification of RET fusion-positive non-small cell lung cancer
    Schweitzer, Brock Lloyd
    Smith, Rebecca B.
    Skelton, Rachel
    Vincent, Ryan
    McMahon, Frank
    Handshoe, John
    Morris, Stephan Wade
    Hout, David Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] A novel RET fusion in non-small cell lung cancer identified by next-generation sequencing: a case report
    Xiaoyi Xu
    Haoyi Wang
    Zhaonan Yu
    Xianguo Chen
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 1825 - 1827
  • [26] A novel RET fusion in non-small cell lung cancer identified by next-generation sequencing: a case report
    Xu, Xiaoyi
    Wang, Haoyi
    Yu, Zhaonan
    Chen, Xianguo
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (07) : 1825 - 1827
  • [27] Current management of RET rearranged non-small cell lung cancer
    Stinchcombe, Thomas E.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [28] The importance of RET-directed therapy in patients with RET-rearranged non-small cell lung cancer
    Yoh, Kiyotaka
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S121 - S123
  • [29] Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion plus Non-Small Cell Lung Cancer
    Oxnard, G.
    Subbiah, V.
    Park, K.
    Bauer, T.
    Wirth, L.
    Velcheti, V.
    Shah, M.
    Besse, B.
    Boni, V.
    Reckamp, K.
    Loong, H.
    Bazhenova, L.
    Solomon, B.
    Tan, D.
    Patel, J.
    Johnson, M.
    Gazzah, A.
    Mok, T.
    Smith, S.
    Tuch, B.
    Ebata, K.
    Zhu, E.
    Nguyen, M.
    Huang, X.
    Cruickshank, S.
    Rothenberg, S.
    Drilon, A.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S349 - S350
  • [30] Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer
    Gao, Ming
    Zhang, Xia
    Yan, Huan
    Sun, Decong
    Yang, Xuejiao
    Yuan, Fang
    Ju, Yanfang
    Wang, Lijie
    Wang, Jinliang
    Zhao, Wei
    Zhang, Dong
    Li, Lin
    Xu, Xiaoyun
    Ma, Junxun
    Hu, Yi
    Zhang, Xiaotao
    SUPPORTIVE CARE IN CANCER, 2023, 31 (12)
12345